Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $12.47 Analyst target: $23.11 Upside: 85.32%
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.